The use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: Antibiotics or anxiolytics?

Infection Control and Hospital Epidemiology

Volumn 31, Issue 11, 2010, Pages 1177-1183

  Shiley, Kevin T ^a   Lautenbach, Ebbing ^a   Lee, Ingi ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CEPHALOSPORIN; DOXYCYCLINE; MACROLIDE; OSELTAMIVIR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADENOVIRUS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG USE; FEMALE; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PARAINFLUENZA VIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK FACTOR; THORAX RADIOGRAPHY; UNITED STATES; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; COHORT STUDIES; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHILADELPHIA; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77957858502     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/656596     Document Type: Article

References (32)

1. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989;23(3):441-451.
2. Loeffler JM, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003;35:843-850.
3. Ayşe E, Aylin Ç, Hürrem B, Mustafa AÇ, Matthew HS, Önder E. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents 2003;21(4):308-312.
4. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ.Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003;163(8):972-978.
5. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302(7):758-766.
6. Fan J, Henrickson KJ, Savatski LL. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 1998;26(6):1397-1402.
7. Byington CL, Castillo H, Gerber K, et al. The effect of rapid respiratory viral diagnostic testing on antibiotic use in a children's hospital. Arch Pediatr Adolesc Med 2002;156(12):1230-1234.
8. Sharma V, Dowd MD, Slaughter AJ, Simon SD. Effect of rapid diagnosis of influenza virus type A on the emergency department management of febrile infants and toddlers. Arch Pediatr Adolesc Med 2002;156(1):41-43.
9. Pianosi P, Feldman W, Robson MG, McGillivray D. Inappropriate use of antibiotics in croup at three types of hospital. CMAJ 1986;134(4):357-359.
10. Doan Q, Enarson P, Kissoon N, Klassen Terry P, Johnson DW. Rapid viral diagnosis for acute febrile respiratory illness in children in the emergency department. Cochrane Database Syst Rev 2009(4):CD006452. http://www.mrw. interscience.wiley.com/cochrane/clsysrev/articles/CD006452/frame.html. Published October 7, 2009. Accessed January 20, 2010.
11. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005;41(10):1438-1444.
12. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007;167(4):354-360.
13. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280(14):1233-1237.
14. Muller AA, Mauny F, Bertin M, et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003;36(8):971-978.
15. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39(4):497-503.
16. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-250.
17. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-723.
18. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(suppl 2):S27-S72.
19. de Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004;125(4):1343-1351.
20. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008;134(6):1141-1148.
21. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008;63(1):42-48.
22. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010;50(2):202-209.
23. Smith PW, Bennett G, Bradley S, et al. SHEA/APIC guideline: infection prevention and control in the long-term care facility. Am J Infect Control 2008;36(7):504-535.
24. Jones P, Bigham R, Manning P. Use of antibiotics in nonbacterial respiratory infections. JAMA 1953;153:262-264.
25. Carrat F, Schwarzinger M, Housset B, Valleron AJ. Antibiotic treatment for influenza does not affect resolution of illness, secondary visits or lost workdays. Eur J Epidemiol 2004;19(7):703-705.
26. Little P, Rumsby K, Kelly J, et al. Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial. JAMA 2005;293(24):3029-3035.
27. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003;187(6):1000-1009.
28. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005;192(2):249-257.
29. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004;190(3):519-526.
30. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163(14):1667-1672.
31. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999;44(suppl B):23-29.
32. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283(8):1016-1024.